Status:
COMPLETED
To Study the Pharmacokinetic and Cardiovascular Effects of Propofol With Respect to Pharmacogenetics in Pakistani Population
Lead Sponsor:
Riphah International University
Collaborating Sponsors:
Holy Family Hospital, Pakistan
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-60 years
Brief Summary
This study aimed to determine the effects of genetic variabilities among the Pakistani population on propofol serum concentration and its adverse effects mainly cardiovascular adverse effects. cardiov...
Detailed Description
Propofol is a phenolic byproduct, available as an oil-in-water intravenous emulsion for calming and mesmerizing purposes. It is among the most widely used intravenous soporific drugs that are used for...
Eligibility Criteria
Inclusion
- Healthy Pakistani individuals between ages 18-60 years undergoing elective surgeries (Open/Laparoscopic guided) induced with propofol.
- Patients in classes I and II of the American Society of Anesthesiologists (ASA) scale.
Exclusion
- Not of Pakistani origin
- Extremes of age
- Patients in classes III, IV, V \&, VI of the ASA scale.
Key Trial Info
Start Date :
January 6 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 14 2022
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05383534
Start Date
January 6 2020
End Date
April 14 2022
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uzma Naeem
Rawalpindi, Punjab Province, Pakistan